Taysha Gene Therapies Inc (NASDAQ: TSHA) is -1.73% lower on its value in year-to-date trading and has touched a low of $1.19 and a high of $4.32 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TSHA stock was last observed hovering at around $1.63 in the last trading session, with the day’s gains setting it 0.07%.
Currently trading at $1.70, the stock is 2.97% and 1.66% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.47 million and changing 4.29% at the moment leaves the stock -22.69% off its SMA200. TSHA registered -47.37% loss for a year compared to 6-month loss of -24.11%.
The stock witnessed a 11.11% gain in the last 1 month and extending the period to 3 months gives it a -47.53%, and is 4.94% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.09% over the week and 9.01% over the month.
Taysha Gene Therapies Inc (TSHA) has around 73 employees, a market worth around $348.50M and $8.33M in sales. Profit margin for the company is -1071.62%. Distance from 52-week low is 42.86% and -60.65% from its 52-week high. The company has generated returns on investments over the last 12 months (-67.04%).
The EPS is expected to shrink by -0.62% this year
The shares outstanding are 204.94M, and float is at 157.70M with Short Float at 15.91%.
The top institutional shareholder in the company is FMR LLC with over 21.21 million shares valued at $47.51 million. The investor’s holdings represent 9.1103 of the TSHA Shares outstanding. As of 2024-06-30, the second largest holder is RTW INVESTMENTS, LP with 18.8 million shares valued at $42.11 million to account for 8.075 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 18.65 million shares representing 8.0104 and valued at over $41.78 million, while BLACKROCK INC. holds 5.0778 of the shares totaling 11.74 million with a market value of $26.3 million.
Taysha Gene Therapies Inc (TSHA) Insider Activity
A total of 0 insider transactions have happened at Taysha Gene Therapies Inc (TSHA) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Manning Paul B, the company’s 10% Owner. SEC filings show that Manning Paul B bought 1,333,333 shares of the company’s common stock on Jun 27 ’24 at a price of $2.25 per share for a total of $3.0 million. Following the purchase, the insider now owns 1.33 million shares.
Taysha Gene Therapies Inc (TSHA): Who are the competitors?
One of the company’s main competitors (and peers) include Sarepta Therapeutics Inc. (SRPT) that is trading -10.51% down over the past 12 months.Amicus Therapeutics Inc. (FOLD) lies in the list of competitors of the Taysha Gene Therapies Inc and is -27.38% lower over the same period from TSHAVoyager Therapeutics Inc. (VYGR) is -55.04% down on the 1-year trading charts.
